Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of EIKEN CHEMICAL CO.,LTD.. A complete text table follows the diagram.
Overseas sales rose 11.3% as fecal-testing reagents and equipment grew, while a new production building and headquarters lifted capital spending and a subsidiary-transfer gain lifted net profit.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Immunoserology reagents | 1 | 11.7B | 57.5% of reported total |
| Other medical equipment and genetics | 1 | 2.9B | 14.3% of reported total |
| Urinalysis reagents | 1 | 2.4B | 11.6% of reported total |
| Microbiology reagents | 1 | 2.1B | 10.5% of reported total |
| Food and environmental media | 1 | 949M | 4.6% of reported total |
| Clinical chemistry reagents | 1 | 300M | 1.5% of reported total |
| Other & rounding | 1 | 2M | 0.0% of reported total |
| Revenue by product category | 2 | 20.4B | Reported six-month total · ¥20.4B |
| Operating profit | 3 | 1.7B | 8.5% operating margin |
| Operating costs & expenses | 3 | 18.7B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 3.7B | Reported pretax result |
| Eiken's overseas fecal-testing growth is lifting the diagnostic portfolio while new capacity absorbs cash | 3 | 2.0B | Overseas sales rose 11.3% as fecal-testing reagents and equipment grew, while a new production building and headquarters lifted capital spending and a subsidiary-transfer gain lifted net profit. |
| Net profit attributable to owners | 5 | 3.0B | Reported parent-company result |
| Tax, attribution & other | 5 | 750M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Immunoserology reagents | Revenue by product category | 11.7B |
| Other medical equipment and genetics | Revenue by product category | 2.9B |
| Urinalysis reagents | Revenue by product category | 2.4B |
| Microbiology reagents | Revenue by product category | 2.1B |
| Food and environmental media | Revenue by product category | 949M |
| Clinical chemistry reagents | Revenue by product category | 300M |
| Other & rounding | Revenue by product category | 2M |
| Revenue by product category | Operating profit | 1.7B |
| Revenue by product category | Operating costs & expenses | 18.7B |
| Operating profit | Profit before tax | 1.7B |
| Eiken's overseas fecal-testing growth is lifting the diagnostic portfolio while new capacity absorbs cash | Profit before tax | 2.0B |
| Profit before tax | Net profit attributable to owners | 3.0B |
| Profit before tax | Tax, attribution & other | 750M |